Many classical ferroptosis inducers, such as erastin and RAS-selective lethal 3, can target the xCT/GPX4 axis, and these inducers can trigger ferroptosis in cancer cells, suggesting they hold promise in the treatment of cancer [40, 42]. This evidence concerns the gene GPX4 and cancer.